Get the Stockscreener App
4.55
3.17%
0.14
After Hours:
4.55
Monte Rosa Therapeutics Inc stock is traded at $4.55, with a volume of 712.39K.
It is up +3.17% in the last 24 hours and down -32.39% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$4.41
Open:
$4.37
24h Volume:
712.39K
Relative Volume:
0.97
Market Cap:
$271.26M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-2.0313
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+9.64%
1M Performance:
-32.39%
6M Performance:
-17.12%
1Y Performance:
-21.55%
1-Day Range:
$4.20
$4.63
1-Week Range:
$4.0112
$4.63
52-Week Range:
$3.21
$12.40
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
4.55 | 271.26M | 0 | -130.41M | -67.76M | -2.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-13-22 | Initiated | UBS | Buy |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Vanguard Group Inc. Buys 622,134 Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Wellington Management Group LLP Grows Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
American Century Companies Inc. Has $533,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
Sei Investments Co. Buys Shares of 17,236 Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
How to Take Advantage of moves in (GLUE) - news.stocktradersdaily.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Holdings Boosted by Charles Schwab Investment Management Inc. - Defense World
Chandra Leo Spends US$58k On Monte Rosa Therapeutics Stock - simplywall.st
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock By Investing.com - Investing.com India
Monte Rosa Therapeutics director Leo Chandra buys $58,383 in stock - Investing.com
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Stock Position Lifted by Bank of New York Mellon Corp - Defense World
Monte Rosa Therapeutics: Exercise Extreme Caution (NASDAQ:GLUE) - Seeking Alpha
FY2029 Earnings Estimate for GLUE Issued By Wedbush - Defense World
Wells Fargo & Company Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price - Defense World
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Q4 2024 Earnings Call Transcript - Insider Monkey
Wedbush Reaffirms Outperform Rating for Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
Promising Clinical Developments and Strategic Partnerships Drive Buy Rating for Monte Rosa Therapeutics - TipRanks
Monte Rosa to focus on prostate cancer only for oncology asset MRT-2359 - MSN
Monte Rosa Therapeutics Earnings Call Highlights Progress and Strategic Shifts - TipRanks
Positive signs for Monte Rosa in early data - The Pharma Letter
Mixed data results for two Monte Rosa molecular glue degraders - Yahoo Finance
Monte Rosa Therapeutics Reports Strong Q4 2024 Results - TipRanks
Monte Rosa Therapeutics announces results from MRT-6160, MRT-2359 programs - TipRanks
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat - Investing.com
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders - Benzinga
Monte Rosa Therapeutics earnings missed by $0.54, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics shares surge on strong Q4 revenue beat By Investing.com - Investing.com Australia
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Monte Rosa Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Earnings call transcript: Monte Rosa Therapeutics Q4 2024 shows strong cash runway - Investing.com
MONTE ROSA THERAPEUTICS Earnings Results: $GLUE Reports Quarterly Earnings - Nasdaq
Monte Rosa Therapeutics sees cash runway into 2028 - TipRanks
Monte Rosa Therapeutics, Inc. SEC 10-K Report - TradingView
Monte Rosa Therapeutics reports Q4 revenue $60.6M, consensus $51.9M - TipRanks
Updated: Monte Rosa reports first data for molecular glue program licensed to Novartis - Endpoints News
Monte Rosa Therapeutics Reports Q4 2024 Financial Results - TipRanks
Monte Rosa Therapeutics Announces Fourth Quarter 2024 - GlobeNewswire
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs - The Manila Times
Monte Rosa's Breakthrough: 90% Target Degradation Success Powers $60M Quarter - StockTitan
Molecular Glues Market to Register Stunning Growth During the Forecast Period (2025-2034) | DelveInsight - Lelezard
When (GLUE) Moves Investors should Listen - news.stocktradersdaily.com
Lexeo Therapeutics (NASDAQ:LXEO) & Monte Rosa Therapeutics (NASDAQ:GLUE) Critical Survey - Defense World
What is Lifesci Capital’s Forecast for GLUE FY2024 Earnings? - Defense World
Monte Rosa Therapeutics (NASDAQ:GLUE) Coverage Initiated at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Monte Rosa Therapeutics (GLUE) with Outperform Recommendation - Nasdaq
Monte Rosa Therapeutics to Present Pipeline Update and - GlobeNewswire
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025 - The Manila Times
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year ... - The Bakersfield Californian
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):